Zilebesiran sodium is a Antisense RNAi Oligonucleotide owned by Alnylam Pharmaceuticals, and is involved in 3 clinical trials, which are ongoing.
Zilebesiran sodium (ALNAGT-01) exhibits anti-hypertensive properties by targeting angiotensinogen. Angiotensinogen (AGT) is the precursor of active angiotensinogen in the renin-angiotensin-aldosterone system. A mutation leading to the replacement of leucine by phenylalanine at position 10 of mature angiotensinogen (L10F), the site of renin cleavage leads to an imbalance in renin-angiotensin-aldosterone system which promotes preeclampsia. The therapeutic candidate, by silencing the human angiotensinogen gene results in therapeutic effect.
The revenue for Zilebesiran sodium is expected to reach a total of $2.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Zilebesiran sodium NPV Report.
Zilebesiran sodium is originated and owned by Alnylam Pharmaceuticals.
Zilebesiran sodium Overview
Zilebesiran sodium (ALNAGT-01) is under development for hypertension. The drug candidate is administered subcutaneously. The drug candidate is an RNAi therapeutic targeting angiotensinogen (AGT) and developed based on enhanced stabilization chemistry (ESC)-GalNAc-conjugate delivery platform technology. It was also under development for the treatment of pre-eclampsia.
Alnylam Pharmaceuticals Overview
Alnylam Pharmaceuticals (Alnylam) is a biopharmaceutical company, which discovers, develops and commercializes drugs based on RNAi interference. The company’s marketed RNAi therapies include Onpattro, which is used in the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis; Givlaari for acute hepatic porphyria, and Oxlumo for primary hyperoxaluria type 1 (PH1). The company develops a broad pipeline of investigational RNAi drugs in the areas of genetic medicines, hepatic infectious, cardio-metabolic, and central nervous system (CNS) diseases. Its late-stage product candidates include vutrisiran for ATTR amyloidosis, inclisiran for hypercholesterolemia, fitusiran for hemophilia and rare bleeding disorders, and lumasiran for severe PH1. The company operates subsidiaries in North America, Europe and Asia-Pacific. Alnylam is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$844.3 million for the fiscal year ended December 2021 (FY2021), an increase of 71.3% over FY2020. The operating loss of the company was US$708.7 million in FY2021, compared to an operating loss of US$828.4 million in FY2020. The net loss of the company was US$852.8 million in FY2021, compared to a net loss of US$858.3 million in FY2020. The company reported revenues of US$264.3 million for the third quarter ended September 2022, an increase of 17.6% over the previous quarter.
Quick View – Zilebesiran sodium
|Highest Development Stage|